Detalhe da pesquisa
1.
Colibactin-positive Escherichia coli induce a procarcinogenic immune environment leading to immunotherapy resistance in colorectal cancer.
Int J Cancer
; 146(11): 3147-3159, 2020 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32037530
2.
Determination of biomarkers associated with neoadjuvant treatment response focusing on colibactin-producing Escherichia coli in patients with mid or low rectal cancer: a prospective clinical study protocol (MICARE).
BMJ Open
; 12(12): e061527, 2022 12 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36460331
3.
Targeting the Tetraspanins with Monoclonal Antibodies in Oncology: Focus on Tspan8/Co-029.
Cancers (Basel)
; 11(2)2019 Feb 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30769765